Form 4: ARWR CEO Anzalone Reports RSU Vesting, Tax-Related Stock Sales

Arrowhead Pharmaceuticals CEO Christopher Anzalone reported the vesting of 180,000 restricted stock units and subsequent sales of 184,298 shares to cover tax obligations.

Summary

• Christopher Richard Anzalone, Chief Executive Officer and Director of Arrowhead Pharmaceuticals, Inc. (ARWR), reported changes in his beneficial ownership.
• On December 12, 2025, 180,000 shares of common stock underlying restricted stock units (RSUs) vested. These RSUs were granted on the same date and will vest in four equal annual installments.
• Between December 15 and December 16, 2025, Anzalone sold a total of 184,298 shares of common stock.
• These sales were exclusively to cover anticipated taxes on performance awards that vested on December 12, 2025.
• The sales occurred at weighted average prices ranging from $59.73 to $70.32 per share.
• Following these transactions, Anzalone's direct beneficial ownership of common stock is 3,916,957 shares.

Sentiment

Score: 5

Explanation: The filing is a routine Form 4 reporting insider transactions related to equity compensation and tax obligations. It does not contain information that would significantly alter the fundamental sentiment towards the company, as the sales are for tax purposes rather than discretionary divestment.

Positives

• Vesting of 180,000 restricted stock units indicates continued equity compensation for the CEO, aligning management interests with shareholders.

Negatives

• The CEO sold a net of 4,298 shares (184,298 shares sold vs. 180,000 shares vested) over the reporting period, slightly reducing overall direct beneficial ownership.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report for a biotechnology company's CEO. Such transactions are common for executives receiving equity compensation and often involve sales to cover tax liabilities upon vesting.

Comparison to Industry Standards

• The reported transactions are standard for executive compensation in the biotechnology and pharmaceutical industries, where restricted stock units and performance awards are common forms of long-term incentives.
• Sales to cover tax obligations upon vesting are also a routine practice and do not necessarily indicate a change in management's outlook on the company's prospects.
• Comparable companies like Moderna (MRNA) or BioNTech (BNTX) also frequently report similar insider transactions related to equity compensation.

Stakeholder Impact

• Shareholders: The CEO's beneficial ownership slightly decreased by 4,298 shares due to tax-related sales, which is a common occurrence and generally not indicative of a change in confidence. The vesting of RSUs aligns the CEO's long-term interests with shareholder value.

Next Steps

• The 180,000 restricted stock units granted on December 12, 2025, will vest in four equal annual installments.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation and tax obligations. The sales are explicitly for tax coverage, not a discretionary divestment, and the CEO also received a significant RSU grant. Therefore, this filing alone does not provide new fundamental information to warrant a change in investment recommendation; a 'hold' stance remains appropriate based solely on this report.

Keywords

Arrowhead Pharmaceuticals, ARWR, Christopher Anzalone, CEO, Form 4, Insider Trading, Stock Sales, RSU Vesting, Equity Compensation, Biotechnology, Pharmaceuticals